Ilya Tsimafeyeu

15PUBLICATIONS
34CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Aug 06, 2026
Consensus statements on the definition, diagnosis, and management of oligoprogressive disease: results of an expert survey of Kazakhstan Cancer Society.

|Jun 23, 2025
Future perspectives: targeting fibroblast growth factor receptor 1 to enhance the efficacy of immunotherapy.

Ilya Tsimafeyeu

|Apr 04, 2025
Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma.

Ilya Tsimafeyeu, Alexander Sultanbaev, Daria Dubovichenko

|Feb 14, 2025
Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real-World, Ambispective RAVE-Bladder Study.

Ilya Tsimafeyeu, Yana Gridneva, Alexander Sultanbaev

|Jan 24, 2025
Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study.

Ilya Tsimafeyeu, Vyacheslav Chubenko, Olga Baklanova

|Sep 23, 2024
Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression.

Ilya Tsimafeyeu

Pageof 3

Frequent Collaborators

2 joint publications

S A Tyulyandin

2 joint publications

Alexey Shkurat

2 joint publications

Rashida Orlova

1 joint publications

M M Byakhova